KẾT QUẢ HÓA TRỊ BỔ TRỢ SAU HÓA XẠ TRỊ TIỀN PHẪU VÀ PHẪU THUẬT UNG THƯ TRỰC TRÀNG GIAI ĐOẠN CT3, 4N1-2M0 TẠI BỆNH VIỆN K

Abstract

Objective: Evaluation of survival time for patients with rectal cancer stage cT3,4N1-2M0 receiving adjuvant chemotherapy after preoperative chemotherapy at K hospital and description some toxicity of adjuvant chemotherapy. Subjects and Methods: Retrospective describe study on 77 patients with stage cT3,4N1-2 rectal cancer who received adjuvant chemotherapy after preoperative chemotherapy at K hospital from January 2017 to December 2018. Results: DFS at 3 years were 82,8% (95%CI 53,2-62,1). The liver and lungs are common sites of recurrence, accounting for 5.2%. OS at 3 years was 90.8% (95%CI 58.7-64.9). The advantageous factors affected on the 3-year disease-free survival include: disease response after chemoradiotherapy (93.3% vs 85%, p < 0.001), stage N0 after chemoradiotherapy treatment (87.3% vs 82.4% vs 0%, p < 0.001), full 6 cycles of chemotherapy (86.8% vs 45%, p=0.001). The advantageous factors affected on the 3 years overall survival: age ≤ 65 (91.5% vs 88.5%, p=0.024), full 6 cycles of chemotherapy (94.1% vs 62.5%, p=0.01). The hematological toxicities were at grade 1 and 2 include anemia (71.4%), leukopenia (50.6%), agranulocytosis (45.5%), thrombocytopenia (39 %). Side effects on the liver and kidneys are rare, mainly grade 1 and 2. Other side effects are less common. Conclusion: Adjuvant chemotherapy for patients with preoperative chemotherapy and radical surgery for rectal cancer is an effective and safe method.